靶向线粒体抗神经退行性疾病新型药物研究进展  

Advances in novel anti-neurodegenerative diseases drugs targeting mitochondria

作　　者：孙竞[1] 高静[1] 

机构地区：[1]江苏大学药学院、线粒体与神经生物学试验室,镇江212013

出　　处：《国际药学研究杂志》2016年第1期79-86,共8页Journal of International Pharmaceutical Research

基　　金：国家自然科学基金资助项目(81373400;81503051);国家自然科学基金委员会(NSFC)与加拿大魁北克医学研究基金会(FRQS)合作研究项目(812111370);江苏省自然科学基金资助项目(BK20140574);江苏大学高级专业人才科研启动基金项目(13JDG063)

摘　　要：线粒体是广泛存在于神经元细胞中的细胞器,它既能通过氧化磷酸化作用为各种生命活动提供能量,也参与了如钙稳态和细胞凋亡等多种病理生理性活动的调节。大量研究证明线粒体功能障碍在帕金森病、阿尔茨海默病等神经退行性疾病的早期发生过程中发挥重要作用。探索线粒体在该类疾病发生过程中的变化,对认识神经退行性疾病的发病机制,开发新型神经保护药物具有重要意义。事实上,一些线粒体靶向性药物已用于神经退行性疾病的临床治疗或正处于不同研究阶段。本文通过对有关线粒体在神经退行性疾病中相关证据的讨论,综述线粒体靶向性神经保护剂的研究进展,论证其作为神经退行性疾病治疗药物的可行性。Mitochondria, the major organelle in neurons, which provides energy via oxidative phosphorylation for all kinds of metabolic activities, is involved in many pathophysiological processes, such as calcium homeostasis and apoptosis. Increasing evidence has indicated that mitochondrial dysfunction displays a significant role in the early stage of neurodegenerative disorders like Parkinson＇s disease （PD） and Alzheimer＇s disease （AD）. Therefore, studies which focus on mitochondrial dysfunction under these pathological conditions contribute to understanding the pathogenesis of neurodegenerative disorder and discovering new neuroprotective drugs. Actually, various mitochondria-targeting agents have been tried in clinic or under different investigational phases against neuro- degenerative disorders. This review discusses the evidence on mitoehondrial impairments during neurodegenerative diseases and the advances in mitochondria-targeting agents as a potential alternative drug strategy for effective management of neurodegenerative diseases.

关 键 词：神经退行性疾病 线粒体靶向性药物 线粒体功能障碍 

分 类 号：R741[医药卫生—神经病学与精神病学]